Rifabutin analogs for the treatment of bacterial diseases

HK40137388APending Publication Date: 2026-09-11BIOVERSYS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124963
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-10
Filing Date
2026-06-17
Publication Date
2026-09-11
Patent Text Reader

Abstract

The present invention relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and / or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments, the bacterial infection is caused by one or more bacterium belonging to a genus of non-tuberculous Mycobacteria, preferably M. abscessus.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract This invention relates to compounds and pharmaceutical compositions comprising said compounds for the treatment, improvement, and / or prevention of diseases. In some embodiments, said disease is a bacterial infection. In some embodiments, said bacterial infection is caused by one or more bacteria belonging to the genus *Mycobacterium*, preferably *Mycobacterium abscessum*.

Claims

CLAIMS 1. A compound of Formula I or a pharmaceutically acceptable salt, tautomer, solvate, hydrate or enantiomer thereof: R1 N O wherein:R1 and R2 are each independently selected from -H, -C1-C6alkyl, -C3-C10cycloalkyl, C1-C6alkylene-C3-C10cycloalkyl, 3- to 15-membered heterocycloalkyl, -C1-C6alkylene-(3- to 15-membered heterocycloalkyl), -C6-C10 aryl, -C1-C6 alkylene-C6-C10 aryl, 5- to 10-membered heteroaryl, and -C1-C6 alkylene-(5- to 10-membered heteroaryl), wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R3; or R1 and R2, together with the nitrogen atom to which they are attached, combine to form a 5- to 15-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one or more R4; R3 is independently, at each occurrence, -OH, halogen, -CN, -C1-C6 alkoxy, -C1-C6 alkyl, -C3-C10cycloalkyl, -C1-C6alkylene-C3-C10cycloalkyl, 3- to 15-membered heterocycloalkyl, -C1-C6alkylene-(3- to 15-membered heterocycloalkyl), -C6-C10aryl, -C1-C6alkylene-C6-C10 aryl, 5- to 10-membered heteroaryl, or -C1-C6 alkylene-(5- to 10-membered heteroaryl); wherein each cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more -OH, halogen, or C1-C6alkyl; R4 is independently, at each occurrence, -C 5 5 1-C6 alkyl, -OR , -C1-C6 alkylene-OR , -NR6R7, -C1-C6 alkylene-NR6R7, -C3-C10 cycloalkyl, -C1-C6 alkylene-C3-C10 cycloalkyl, 3- to 15-membered heterocycloalkyl, -C1-C6alkylene-(3- to 15-membered heterocycloalkyl), -C6- C10 aryl, -C1-C6 alkylene-C6-C10 aryl, 5- to 10-membered heteroaryl, or -C1-C6 alkylene-(5- to 10-membered heteroaryl), wherein each alkylene is optionally substituted with one or more oxo, and wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one or more R8; R5 is independently, at each occurrence, -H, -C1-C6 alkyl, or -C1-C6 alkylene-OH; R6 and R7 are each independently, at each occurrence, -H, -C1-C6alkyl, -C3-C10cycloalkyl, 3- to 15-membered heterocycloalkyl, C6-C10aryl, or 5- to 10-membered heteroaryl; and R8 is independently, at each occurrence, -OH, halogen, or -C1-C6alkyl.

2. The compound of claim 1, wherein R1 and R2 are each independently selected from -H, -C1-C4 alkyl, -C3-C10 cycloalkyl, C1-C4 alkylene-C3-C10 cycloalkyl, -5- to 15-membered heterocycloalkyl, and -C1-C4alkylene-(5- to 15-membered heterocycloalkyl), wherein each alkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R3; or R1 and R2, together with the nitrogen atom to which they are attached, combine to form a 5- to 15-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one or more R4; R3 is independently, at each occurrence, -OH, halogen, -C1-C4 alkyl, -C3-C10 cycloalkyl, -C1-C4 alkylene-C3-C10 cycloalkyl, 5- to 15-membered heterocycloalkyl, -C1-C4 alkylene-(5- to 15-membered heterocycloalkyl), -C6-C10aryl, -C1-C4alkylene-C6-C10aryl, 5- to 10-membered heteroaryl, or -C1-C4alkylene-(5- to 10-membered heteroaryl); wherein each cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more -OH, halogen, or C1-C4 alkyl; R4 is independently, at each occurrence, -C 5 5 1-C6 alkyl, -OR , -C1-C4 alkylene-OR , - NR6R7, -C1-C4 alkylene-NR6R7, -C3-C10 cycloalkyl, -C1-C4 alkylene-C3-C10 cycloalkyl, 5- to 15-membered heterocycloalkyl, -C1-C4alkylene-(5- to 15-membered heterocycloalkyl), -C6- C10 aryl, -C1-C4 alkylene-C6-C10 aryl, 5- to 10-membered heteroaryl, or -C1-C4 alkylene-(5- to 10-membered heteroaryl), wherein each alkylene is optionally substituted with one or more oxo; and wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one or more R8; R5is independently, at each occurrence, -H, -C1-C4alkyl, or -C1-C4alkylene-OH;R6 and R7 are each independently, at each occurrence, -H, -C1-C4 alkyl, -C3-C10 cycloalkyl, 5- to 10-membered heterocycloalkyl, C6-C10aryl, or 5- to 10-membered heteroaryl; and R8is independently, at each occurrence, -OH, halogen, or -C1-C4alkyl.

3. The compound of claim 1 or 2, wherein R1 and R2 are each independently selected from -H, -5- to 15-membered heterocycloalkyl, and -C1-C4 alkylene-(5- to 15-membered heterocycloalkyl), wherein each heterocycloalkyl is optionally substituted with one or more R3; or R1and R2, together with the nitrogen atom to which they are attached, combine to form a 5- to 15-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one or more R4; R3 is independently, at each occurrence, -OH, halogen, -C1-C4alkyl, -C3-C10cycloalkyl, -C1-C4 alkylene-C3-C10 cycloalkyl, 5- to 15-membered heterocycloalkyl, -C1-C4 alkylene-(5- to 15-membered heterocycloalkyl), -C6-C10aryl, -C1-C4alkylene-C6-C10aryl, 5- to 10-membered heteroaryl, or -C1-C4 alkylene-(5- to 10-membered heteroaryl); wherein each cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more -OH, halogen, or C1-C4alkyl; R4 is independently, at each occurrence, -C1-C6alkyl, -OR5, -C1-C4alkylene-OR5, - NR6R7, -C1-C4 alkylene-NR6R7, -C3-C10 cycloalkyl, -C1-C4 alkylene-C3-C10 cycloalkyl, 5- to 15-membered heterocycloalkyl, -C1-C4 alkylene-(5- to 15-membered heterocycloalkyl), -C6- C10aryl, -C1-C4alkylene-C6-C10aryl, 5- to 10-membered heteroaryl, or -C1-C4alkylene-(5- to 10-membered heteroaryl), wherein each alkylene is optionally substituted with one or more oxo; and wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one or more R8; R5 is independently, at each occurrence, -H, -C1-C4 alkyl, or -C1-C4 alkylene-OH; R6and R7are each independently, at each occurrence, -H, -C1-C4 alkyl, -C3-C10 cycloalkyl, 5- to 6-membered heterocycloalkyl, C6-C10aryl, or 5- to 10-membered heteroaryl; and R8 is independently, at each occurrence, halogen or -C1-C4 alkyl.

4. The compound of any of claims 1 to 3, wherein R1 and R2 are each independently selected from -H, -C1-C6alkyl, -C3-C6cycloalkyl, C1-C6alkylene-C3-C6cycloalkyl, -5- to 6-membered heterocycloalkyl, -C1-C6 alkylene-(5- to 6-membered heterocycloalkyl), -C6-C10 aryl, -C1-C6alkylene-C6-C10aryl, 5- to 6-membered heteroaryl, or -C1-C6alkylene-(5- to 6- membered heteroaryl), wherein each cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R3.

5. The compound of any of claims 1 to 4, wherein R1 and R2 are each independently selected from -H, -5- to 12-membered heterocycloalkyl, and -C1-C4 alkylene-(5- to 12- membered heterocycloalkyl), wherein each heterocycloalkyl is optionally substituted with one or more R3; and R3is independently, at each occurrence, -C1-C4 alkyl, -C3-C10 cycloalkyl, -C1-C4 alkylene-C3-C10cycloalkyl, 5- to 12-membered heterocycloalkyl, -C1-C4alkylene-(5- to 12- membered heterocycloalkyl), -C6-C10 aryl, -C1-C4 alkylene-C6-C10 aryl, 5- to 10-membered heteroaryl, or -C1-C4alkylene-(5- to 10-membered heteroaryl); wherein each cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more C1-C4 alkyl.

6. The compound of any of claims 1 to 5, wherein R1is -H; R2 is independently selected from -5- to 6-membered heterocycloalkyl and -C1-C2 alkylene-(5- to 6-membered heterocycloalkyl), wherein each heterocycloalkyl is optionally substituted with one or more R3; and R3 is independently, at each occurrence, -C1-C4 alkyl, -C3-C6 cycloalkyl, -C1-C2 alkylene-C3-C6 cycloalkyl, 5- to 6-membered heterocycloalkyl, -C1-C2 alkylene-(5- to 6- membered heterocycloalkyl), -C6- aryl, -C1-C2alkylene-C6aryl, 5- to 6-membered heteroaryl, or -C1-C2 alkylene-(5- to 6-membered heteroaryl); wherein each cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more C1-C2alkyl.

7. The compound of any of claims 1 to 3, wherein R1 and R2, together with the nitrogen atom to which they are attached, combine to form a 5- to 15-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one or more R4.

8. The compound of any of claims 1 to 3 or 7, wherein R1 and R2, together with the nitrogen atom to which they are attached, combine to form a 5- to 12-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one or more R4; R4is independently, at each occurrence, -C1-C6alkyl, -OR5, -C1-C4alkylene-OR5, -NR6R7, -C1-C4 alkylene-NR6R7, -C5-C10 cycloalkyl, -C1-C4 alkylene-C5-C10 cycloalkyl, 5- to 12-membered heterocycloalkyl, -C1-C4alkylene-(5- to 12-membered heterocycloalkyl), phenyl, -C1-C4 alkylene-phenyl, 5- to 10-membered heteroaryl, or -C1-C4 alkylene-(5- to 10- membered heteroaryl), wherein each alkylene is optionally substituted with one or more oxo; and wherein each alkyl, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is optionally substituted with one or more R8; R5 is independently, at each occurrence, -H, -C1-C4 alkyl, or -C1-C4 alkylene-OH; R6 and R7 are each independently, at each occurrence, -H, -C1-C4alkyl, -C5-C6cycloalkyl, 5- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl; and R8is independently, at each occurrence, halogen or -C1-C4 alkyl.

9. The compound of any of claims 1 to 3 or 7 to 8, wherein R1 and R2, together with the nitrogen atom to which they are attached, combine to form a 6- to 7-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one or more R4; R4 is independently, at each occurrence, -C1-C6alkyl, -OR5, -C1-C4alkylene-OR5, - NR6R7, -C1-C4 alkylene-NR6R7, -C5-C6 cycloalkyl, -C1-C4 alkylene-C5-C6 cycloalkyl, 5- to 6- membered heterocycloalkyl, -C1-C4 alkylene-(5- to 6-membered heterocycloalkyl), phenyl, - C1-C4alkylene-phenyl, 5- to 6-membered heteroaryl, or -C1-C4alkylene-(5- to 6-membered heteroaryl), wherein each alkylene is optionally substituted with one or more oxo; and wherein each alkyl, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is optionally substituted with one or more R8; R5 is independently, at each occurrence, -H, -C1-C4alkyl, or -C1-C4alkylene-OH; R6 and R7 are each independently, at each occurrence, -H, -C1-C4 alkyl, -C5-C6 cycloalkyl, 5- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl; and R8 is independently, at each occurrence, halogen or -C1-C4 alkyl.

10. The compound according to claim 1, wherein the compound is selected from the groupconsisting of:

11. The compound according to claim 1, wherein the compound is selected from the groupconsisting of:or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 1, wherein the compound is selected from the groupconsisting of:or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising at least one compound according to any of the preceding claims, or a pharmaceutically acceptable salt, tautomer, solvate or hydrate thereof, and a pharmaceutically acceptable excipient.

14. A compound according to any of the claims 1 to 12 or a pharmaceutically acceptable salt, tautomer, solvate or hydrate thereof, for use as a medicament.

15. A compound of according to any of the claims 1 to 12 or a pharmaceutically acceptable salt, tautomer, solvate or hydrate thereof, for use in a method of preventing or treating a disease in a subject, preferably wherein said disease is an infection, further preferably a bacterial infection, yet further preferably a bacterial infection caused by one or more bacterium belonging to a genus of non-tuberculous Mycobacteria, preferably M. abscessus.